title: The Effect of Teriparatide on Fracture Healing of Osteoporotic Patients: A Meta-Analysis of Randomized Controlled Trials.
abstract: Purpose. This meta-analysis is to assess the effectiveness of teriparatide in fracture healing and clinical function improvement of the osteoporotic patients. Methods. We searched PubMed, Embase, Web of Science, and the Cochrane databases for randomized and quasi-randomized controlled trials comparing teriparatide to placebo, no treatment, or comparator interventions in the osteoporotic patients. Results. Five studies with 251 patients were included. Patients treated with teriparatide therapy had a significant shorter radiological fracture healing time compared with those in the control group (mean difference [MD] -4.54 days, 95% confidence interval [CI] -8.80 to -0.28). Stratified analysis showed that lower limb group had significant shorter healing time (MD -6.24 days, 95% CI -7.20 to -5.29), but upper limb group did not (MD -1 days, 95% CI -2.02 to 0.2). Patients treated with teriparatide therapy showed better functional outcome than those in the control group (standardized mean difference [SMD] -1.02, 95% CI -1.81 to -0.22). Patients with therapy duration over 4 weeks would have better functional outcome (SMD -1.68, 95% CI -2.07 to -1.29). Conclusions. Teriparatide is effective in accelerating fracture healing and improving functional outcome of osteoporotic women. However, more clinical studies are warranted in order to determine whether the results are applicable to males and the clinical indications for teriparatide after osteoporotic fractures.
authors.affiliation: Department of Orthopedics, General Hospital of Chinese PLA, Beijing, China.
authors.forename: Shenghan
authors.initials: S
authors.lastname: Lou
authors.affiliation: Department of Orthopedics, General Hospital of Chinese PLA, Beijing, China.
authors.forename: Houchen
authors.initials: H
authors.lastname: Lv
authors.affiliation: Department of Orthopedics, General Hospital of Chinese PLA, Beijing, China.
authors.forename: Guoqi
authors.initials: G
authors.lastname: Wang
authors.affiliation: Department of Orthopedics, General Hospital of Chinese PLA, Beijing, China.
authors.forename: Licheng
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of Orthopedics, General Hospital of Chinese PLA, Beijing, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Li
authors.affiliation: Department of Orthopedics, General Hospital of Chinese PLA, Beijing, China.
authors.forename: Zhirui
authors.initials: Z
authors.lastname: Li
authors.affiliation: Department of Orthopedics, General Hospital of Chinese PLA, Beijing, China.
authors.forename: Lihai
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of Orthopedics, General Hospital of Chinese PLA, Beijing, China.
authors.forename: Peifu
authors.identifier: 0000-0003-4279-1704
authors.initials: P
authors.lastname: Tang
mesh_terms: D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D005260:Female; D017102:Fracture Healing / Q000187:drug effects*; D006801:Humans; D058866:Osteoporotic Fractures / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000453:epidemiology*; D015995:Prevalence; D016032:Randomized Controlled Trials as Topic; D017678:Sex Distribution; D019379:Teriparatide / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide